Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (339)	4/15/2002 4:26:10 PM
From: tuck	Read Replies (4) \| Respond to of 544

Bernard, Got any thoughts on TLRK, GZMO, & BTRN from a TA perspective? All of these touched lows on better than average volume today. Climaxes, or more downside due? TLRK, in particular, has a large short position, probably because few think T67 will do much in the indications in which it is being tested. But the rest of the pipe looks good, and it has some cash. GZMO possibly down on no SAGE deals and leaked bad ASCO results (guessing with the rest of us peons on the latter). BTRN will probably need to finance, and MEDI is slow and won't take Rick's suggestion of testing 507 at low doses. All of this is history, so the TA future is . . . ? BDAL also near lows with a large short position. Management has been hitting targets and recently declared good visibility for the next couple of quarters, so the only fundamental reason for the attack would be a belated focus on valuation, which is actually looking pretty reasonable in the $8 range. Cheers, Tuck